Haleon (HLN) Current Assets (2021 - 2026)

Haleon's (HLN) quarterly Current Assets came in at $5.8 billion in Q2 2026, down 5.56% on a QoQ basis from $6.1 billion in Q4 2025.

Haleon (HLN) Current Assets (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Current Assets data on file, last reported at $5.8 billion in Q2 2026.

Quarterly Current Assets changed N/A year-over-year to $5.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.8 billion (changed N/A YoY) and the FY2025 annual result came in at $6.1 billion, down 17.2% from the prior year.
Current Assets declined to $5.8 billion in Q2 2026, from $6.1 billion in the prior quarter.
In the past five years, Current Assets ranged from a high of $18.1 billion in Q2 2022 to a low of $4.8 billion in Q4 2022.
A 5-year average of $7.4 billion and a median of $6.0 billion in 2023 frame the typical range for Current Assets.
The widest YoY moves for Current Assets: up 25.6% in 2023, down 71.0% in 2023.
Tracing HLN's Current Assets over 5 years: stood at $4.8 billion in 2022, then grew by 25.6% to $6.0 billion in 2023, then gained by 22.73% to $7.3 billion in 2024, then slipped by 16.94% to $6.1 billion in 2025, then retreated by 5.56% to $5.8 billion in 2026.
The last three Current Assets figures came in at $5.8 billion (Q2 2026), $6.1 billion (Q4 2025), and $7.3 billion (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Assets (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	5.76 Bn
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	13.76 Bn
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	6.36 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	19.76 Bn
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	3.48 Bn
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	10.06 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	1.64 Bn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	3.80 Bn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	3.22 Bn
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	1.52 Bn

Download Data